Lawyers Comment On High Court's Pay-For-Delay Decision
Law360, New York (June 17, 2013, 6:34 PM EDT) -- The U.S. Supreme Court ruled Monday that brand-name drugmakers can be sued for paying generic-drug manufacturers to delay the release of low-cost versions of blockbuster medicines, overturning an Eleventh Circuit finding that the agreements were generally legal. Here, attorneys tell Law360 why the 5-3 decision in Federal Trade Commission v. Actavis Inc. is significant.
Alden Atkins, Vinson & Elkins LLP
"The court's decision stands out because it says that an agreement that is entirely within the scope of a patent may violate the antitrust laws, without...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.